
Verona Pharma PLC
NASDAQ:VRNA

Intrinsic Value
The intrinsic value of one
VRNA
stock under the Base Case scenario is
40.49
USD.
Compared to the current market price of 57.91 USD,
Verona Pharma PLC
is
Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Verona Pharma PLC
Fundamental Analysis


Revenue & Expenses Breakdown
Verona Pharma PLC
Balance Sheet Decomposition
Verona Pharma PLC
Current Assets | 453.6m |
Cash & Short-Term Investments | 399.8m |
Receivables | 37.3m |
Other Current Assets | 16.6m |
Non-Current Assets | 20.7m |
Long-Term Investments | 15m |
PP&E | 3.2m |
Intangibles | 545k |
Other Non-Current Assets | 2m |
Free Cash Flow Analysis
Verona Pharma PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Verona Pharma PLC
Revenue
|
42.3m
USD
|
Cost of Revenue
|
-2.6m
USD
|
Gross Profit
|
39.7m
USD
|
Operating Expenses
|
-194.3m
USD
|
Operating Income
|
-154.6m
USD
|
Other Expenses
|
-18.8m
USD
|
Net Income
|
-173.4m
USD
|
VRNA Profitability Score
Profitability Due Diligence
Verona Pharma PLC's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Score
Verona Pharma PLC's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
VRNA Solvency Score
Solvency Due Diligence
Verona Pharma PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Score
Verona Pharma PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRNA Price Targets Summary
Verona Pharma PLC
According to Wall Street analysts, the average 1-year price target for
VRNA
is 81.94 USD
with a low forecast of 72.72 USD and a high forecast of 97.65 USD.
Dividends
Current shareholder yield for VRNA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
VRNA
stock under the Base Case scenario is
40.49
USD.
Compared to the current market price of 57.91 USD,
Verona Pharma PLC
is
Overvalued by 30%.